Amendment “New nomenclature for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)” to the S2k guideline “Non-alcoholic fatty liver disease” (v.2.0/April 2022) of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Authors; Collaborators

doi:10.1055/a-2408-3429

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2024; 62(12): 2065-2074
DOI: 10.1055/a-2408-3429

Leitlinie

Amendment “New nomenclature for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)” to the S2k guideline “Non-alcoholic fatty liver disease” (v.2.0/April 2022) of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

March 2024 – AWMF Register Number: 021-025

Authors

(

Elke Roeb

¹Gastroenterology, Medical Clinic II, University Hospital Gießen and Marburg, Gießen, Germany

Ali Canbay

²Medical Clinic, University Hospital Knappschaftskrankenhaus Bochum, Bochum, Germany

Heike Bantel

³Clinic for Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School (MHH), Hannover, Germany

Jörg Bojunga

⁴Medical Clinic I Gastroenterology, Hepatology, Pneumology, Endocrinology, University Hospital Frankfurt, Frankfurt, Germany

Jan de Laffolie

⁵General Pediatrics and Neonatology, Center for Pediatrics and Adolescent Medicine, University Hospital Giessen and Marburg, Giessen, Germany

Münevver Demir

⁶Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany

Ulrike W. Denzer

⁷Clinic for Gastroenterology, Endocrinology, Metabolism and Clinical Infectiology, University Hospital Giessen and Marburg, Marburg, Germany

Andreas Geier

⁸Medical Clinic and Polyclinic II, Focus on Hepatology, University Hospital Würzburg, Würzburg, Germany

Wolf Peter Hofmann

⁹Gastroenterology at Bayerischer Platz – Medical Care Center, Berlin, Germany

Christian Hudert

¹⁰Department of Pediatrics with specialization in Gastroenterology, Nephrology and Metabolic Medicine, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

Thomas Karlas

¹¹Clinic and Polyclinic for Oncology, Gastroenterology, Hepatology, Pneumology and Infectiology, Leipzig University Hospital, Leipzig, Germany

Marcin Krawczyk

¹²Department of Internal Medicine II (Gastroenterology, Hepatology, Endocrinology, Diabetology and Nutritional Medicine), Saarland University Hospital, Homburg, Germany

Thomas Longerich

¹³Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

Tom Lüdde

¹⁴Clinic for Gastroenterology, Hepatology and Infectiology, Düsseldorf University Hospital, Düsseldorf, Germany

Michael Roden

¹⁵Clinic for Endocrinology and Diabetology, Düsseldorf University Hospital, Düsseldorf, Germany

Jörn M. Schattenberg

¹²Department of Internal Medicine II (Gastroenterology, Hepatology, Endocrinology, Diabetology and Nutritional Medicine), Saarland University Hospital, Homburg, Germany

Martina Sterneck

¹⁶Clinic for Hepatobiliary Surgery and Transplantation Surgery, University Hospital Hamburg, Hamburg, Germany

Andrea Tannapfel

¹⁷Institute of Pathology, Ruhr University Bochum, Bochum, Germany

Pia Lorenz

¹⁸German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS), Berlin, Germany

Frank Tacke

⁶Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany

)

References
1 Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542-1556
2 Ludwig J, Viggiano TR, McGill DB. et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438
3 Geier A, Tiniakos D, Denk H. et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021; 70: 1570-1579
4 Roeb E, Canbay A, Bantel H. et al. Updated S2k guideline non-alcoholic fatty liver disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF registry number: 021-025. Z Gastroenterol 2022; 60: 1346-1421
5 Roeb E, Steffen HM, Bantel H. et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 2015; 53: 668-723
6 Eslam M, Newsome PN, Sarin SK. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73: 202-209
7 Loomba R, Ratziu V, Harrison SA. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology 2022; 162: 680-688
8 Israelsen M, Torp N, Johansen S. et al. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol 2023; 8: 866-868
9 Åberg F, Byrne CD, Pirola CJ. et al. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol 2023; 78: 191-206
10 Ciardullo S, Carbone M, Invernizzi P. et al. Exploring the landscape of steatotic liver disease in the general US population. Liver Int 2023; 43: 2425-2433
11 Mózes FE, Lee JA, Vali Y. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 704-713
12 Vali Y, Lee J, Boursier J. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol 2023; 8: 714-725
13 Hardy T, Wonders K, Younes R. et al. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020; 98: 106175
14 Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and sub-classifications using consensus nomenclature. Hepatology 2023;
15 Hagström H, Vessby J, Ekstedt M. et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 2023;
16 Siddiqui MS, Harrison SA, Abdelmalek MF. et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018; 67: 2001-2012
17 Younossi ZM, Stepanova M, Taub RA. et al. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2022; 20: 1354-1361
18 Harrison SA, Taub R, Neff GW. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2023; 29: 2919-2928
19 Li M, Zhang W, Li X. et al. Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults. Nutrients 2023; 15
20 Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther 2017; 46: 85-95

Supplementary Material

Supplementary material (PDF) (opens in new window)